Equities analysts predict that Merus (NASDAQ:MRUS) will report sales of $10.53 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Merus’ earnings. The lowest sales estimate is $8.34 million and the highest is $13.00 million. Merus posted sales of $8.57 million in the same quarter last year, which suggests a positive year-over-year growth rate of 22.9%. The business is expected to announce its next earnings report on Thursday, November 4th.
On average, analysts expect that Merus will report full year sales of $40.01 million for the current fiscal year, with estimates ranging from $27.43 million to $47.38 million. For the next fiscal year, analysts expect that the business will post sales of $34.14 million, with estimates ranging from $13.33 million to $49.74 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Merus.
Merus (NASDAQ:MRUS) last released its earnings results on Thursday, August 5th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.13). Merus had a negative return on equity of 51.93% and a negative net margin of 231.19%. The business had revenue of $12.38 million for the quarter, compared to analysts’ expectations of $7.83 million.
In other news, SVP Lex Bakker sold 3,860 shares of the stock in a transaction dated Thursday, July 1st. The shares were sold at an average price of $21.05, for a total transaction of $81,253.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Bvf Partners L. P/Il sold 2,186,022 shares of the stock in a transaction dated Friday, July 2nd. The stock was sold at an average price of $20.75, for a total transaction of $45,359,956.50. The disclosure for this sale can be found here. Insiders sold 2,192,669 shares of company stock worth $45,495,110 in the last ninety days. 2.90% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Macquarie Group Ltd. purchased a new stake in shares of Merus during the second quarter worth approximately $27,000. UBS Group AG increased its stake in shares of Merus by 214.8% during the first quarter. UBS Group AG now owns 2,899 shares of the biotechnology company’s stock worth $61,000 after buying an additional 1,978 shares during the period. Citigroup Inc. increased its stake in shares of Merus by 3,238.6% during the second quarter. Citigroup Inc. now owns 7,779 shares of the biotechnology company’s stock worth $164,000 after buying an additional 7,546 shares during the period. Jump Financial LLC purchased a new stake in shares of Merus during the second quarter worth approximately $202,000. Finally, Virtus ETF Advisers LLC purchased a new stake in shares of Merus during the second quarter worth approximately $208,000. 69.61% of the stock is currently owned by institutional investors and hedge funds.
Shares of Merus stock traded down $0.73 during trading hours on Wednesday, reaching $22.21. 63,263 shares of the company’s stock were exchanged, compared to its average volume of 206,332. Merus has a 1 year low of $11.19 and a 1 year high of $31.27. The business has a fifty day moving average of $22.16 and a two-hundred day moving average of $21.83. The company has a market capitalization of $854.60 million, a P/E ratio of -8.17 and a beta of 0.59.
Merus Company Profile
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.
Featured Story: How do buyers and sellers choose a strike price?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.